CYTOVERA, INC. — Department of Health and Human Services SBIR Phase II: DESCRIPTION (provided by applicant): This project aims to continue development and validat
CYTOVERA, INC. — SBIR Phase II award from Department of Health and Human Services.
- Amount
- $810,130
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase II
- Solicitation
- PA13-234
- NAICS
- —
- Place of performance
- MA
- Period
- —
Description
DESCRIPTION (provided by applicant): This project aims to continue development and validation of a novel microfluidics device developed during Phase I that preserves the maximal viability, recovery, and function of cord blood hematopoietic stem cells (HSC). Allogeneic HSC transplantation is the elective treatment for over 50 life threatening diseases including leukemia and lymphoma. However due to matching donor availability, fewer than 30% of the patients actually receive one. Umbilical cord blood has emerged as a readily available source of HSC as it has been collected and stored in cord blood banks worldwide. However, the number of viable HSC in the units stored today is insufficient to effectively treat adult patients. For the 1yr survval rate of adult patients to be significantly increased from the current ~20% to the 50% - 70% success rate achieved in children, it is estimated that the number of viable HSC in a transplanted cord blood unit has to be increased by a factor of ~3. Studies have shown t